Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
10.3969/j.issn.1673-4254.2015.03.27
- VernacularTitle:吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较
- Author:
Yalin XIE
1
;
Jizhen LIANG
;
Ning SU
Author Information
1. 广州市胸科医院肿瘤科
- Keywords:
advanced non-small-cell lung cancer;
Gefitinib;
Erlotinib;
EGFR gene;
mutation-positive
- From:
Journal of Southern Medical University
2015;(3):446-449
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with untreated advanced EGFR mutation-positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). The progression-free survival, objective response rate and disease control rate were evaluated to compare the efficacy of gefitinib and erlotinib. Results There were no significant differences in the objective response rate (P=0.711) and disease control rate (P=0.861) between the two groups. The progression-free survival of gefitinib group and erlotinib group was 8.0 months and 10.0 months, respectively. The efficacy of the two drugs was similar (P=0.293). Conclusion There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.
